Skip to main content
Springer Nature Link
Log in

Atrial and Brain Natriuretic Peptides

  • Reference work entry
  • First Online:
Encyclopedia of Molecular Pharmacology

  • 317 Accesses

Synonyms

Atrial natriuretic factor/B-type natriuretic peptide

Definition

Atrial natriuretic peptide (ANP) and brain (also known as B-type) natriuretic peptide (BNP) are biologically active molecules that belong to the natriuretic peptide family, which also includes a third member, C-type natriuretic peptide (CNP). ANP was first isolated from human atrial tissue and its complete amino acid sequence was determined in 1984 (Kangawa and Matsuo 1984). BNP was first identified in porcine brain tissue in 1988. It is now known, however, that both ANP and BNP are secreted by the heart and act as cardiac hormones. In response to stretching of the myocardium, the two peptides are secreted from cardiomyocytes into the circulation. Both ANP and BNP preferentially bind to natriuretic peptide receptor-A (NPR-A or guanylyl cyclase-A) and exert similar effects through increases in intracellular cyclic guanosine monophosphate (cGMP) within target tissues. Through this action, they induce a decrease in...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH et al (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure National Registry (ADHERE). J Am Coll Cardiol 46(1):57–64

    PubMed  Google Scholar 

  • Bayes-Genis A, Barallat J, Richards AM (2016) A test in context: Neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 68(6):639–653

    CAS  PubMed  Google Scholar 

  • Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR et al (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10(7):607–613

    CAS  PubMed  Google Scholar 

  • Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD et al (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med 343(4):246–253

    CAS  PubMed  Google Scholar 

  • Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F et al (2004) Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 44(5):746–750

    CAS  PubMed  Google Scholar 

  • Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T et al (2008) Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J 72(11):1787–1793

    CAS  PubMed  Google Scholar 

  • John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC et al (1995) Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267(5198):679–681

    CAS  PubMed  Google Scholar 

  • Kangawa K, Matsuo H (1984) Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 118(1):131–139

    CAS  PubMed  Google Scholar 

  • Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Muller-Esch G (1996) Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 51(3–4):269–272

    CAS  PubMed  Google Scholar 

  • Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T et al (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370(9597):1483–1493

    CAS  PubMed  Google Scholar 

  • Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O et al (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107(8):975–984

    CAS  PubMed  PubMed Central  Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004

    PubMed  Google Scholar 

  • Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr et al (2007) Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 49(6):716–726

    CAS  PubMed  Google Scholar 

  • Nakagawa Y, Nishikimi T, Kuwahara K (2019) Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides 111:18–25

    CAS  PubMed  Google Scholar 

  • Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69(2):318–328

    CAS  PubMed  Google Scholar 

  • Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57(2):131–140

    PubMed  Google Scholar 

  • O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365(1):32–43

    PubMed  Google Scholar 

  • Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL et al (1997) Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 94(26):14730–14735

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37(27):2129–2200

    PubMed  Google Scholar 

  • Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 170(6):507–514

    CAS  PubMed  Google Scholar 

  • Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H et al (1993) Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 11(4):407–416

    CAS  PubMed  Google Scholar 

  • Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S et al (2009) Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study. J Am Coll Cardiol 54(12):1058–1064

    CAS  PubMed  Google Scholar 

  • Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M et al (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97(8):4239–4244

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M et al (2019) JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure- digest version. Circ J 83(10):2084–2184

    PubMed  Google Scholar 

  • Volpe M, Carnovali M, Mastromarino V (2016) The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 130(2):57–77

    CAS  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation 136(6):e137–ee61

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Yasuaki Nakagawa

  2. Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

    Koichiro Kuwahara

Authors
  1. Yasuaki Nakagawa
    View author publications

    Search author on:PubMed Google Scholar

  2. Koichiro Kuwahara
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Koichiro Kuwahara .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany

    Stefan Offermanns

  2. Medical Faculty, Goethe University, Frankfurt, Germany

    Stefan Offermanns

  3. Friedrich-Schiller University Jena, Jena, Germany

    Walter Rosenthal

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nakagawa, Y., Kuwahara, K. (2021). Atrial and Brain Natriuretic Peptides. In: Offermanns, S., Rosenthal, W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7_10066

Download citation

Publish with us

Policies and ethics